TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome
Brief Summary: Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.


Options:
A: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minalcipran; Type: EXPERIMENTAL; Interventions: Drug: milnacipran | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran
D: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome
Brief Summary: Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minalcipran; Type: EXPERIMENTAL; Interventions: Drug: milnacipran | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
D: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome
Brief Summary: Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minalcipran; Type: EXPERIMENTAL; Interventions: Drug: milnacipran | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Expanded Chronic Care Model: Targeting Disparities in Diabetes Care
Brief Summary: The goal of this study is to investigate methods of improving diabetes care for African Americans in primary care clinics. Primary care clinicians will receive training in the delivery of cross-cultural medicine as well as regular performance feedback reports.


Options:
A: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
B: Intervention Type: BEHAVIORAL; Name: TRANSLATE; Assigned to Arm(s): N/A
C: Arm Label: Feedback report only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Goal-Setting Worksheet; Type: EXPERIMENTAL; Interventions: Other: Worksheet to facilitate goal-setting and action plans | Intervention Type: OTHER; Name: Worksheet to facilitate goal-setting and action plans; Assigned to Arm(s): Goal-Setting Worksheet
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Expanded Chronic Care Model: Targeting Disparities in Diabetes Care
Brief Summary: The goal of this study is to investigate methods of improving diabetes care for African Americans in primary care clinics. Primary care clinicians will receive training in the delivery of cross-cultural medicine as well as regular performance feedback reports.


Options:
A: Arm Label: minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: professional audit and feedback (guideline adherence) | Arm Label: maximal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: patient education, Behavioral: professional audit and feedback (guideline adherence), Behavioral: professional education (communication/shared decision making), Other: information tools | Intervention Type: BEHAVIORAL; Name: patient education; Assigned to Arm(s): maximal intervention | Intervention Type: BEHAVIORAL; Name: professional audit and feedback (guideline adherence); Assigned to Arm(s): maximal intervention, minimal intervention | Intervention Type: BEHAVIORAL; Name: professional education (communication/shared decision making); Assigned to Arm(s): maximal intervention | Intervention Type: OTHER; Name: information tools; Assigned to Arm(s): maximal intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Electronic feedback system on diabetes care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic feedback system on diabetes care; Assigned to Arm(s): Intervention
C: Intervention Type: PROCEDURE; Name: meeting nurses / physicians, quality improvement sessions; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Expanded Chronic Care Model: Targeting Disparities in Diabetes Care
Brief Summary: The goal of this study is to investigate methods of improving diabetes care for African Americans in primary care clinics. Primary care clinicians will receive training in the delivery of cross-cultural medicine as well as regular performance feedback reports.


Options:
A: Intervention Type: BEHAVIORAL; Name: Motivational Interview with care plan and education; Assigned to Arm(s): N/A
B: Arm Label: Use of a Patient Navigator; Type: EXPERIMENTAL; Interventions: Other: Patient navigation | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Patient navigation; Assigned to Arm(s): Use of a Patient Navigator | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
C: Intervention Type: BEHAVIORAL; Name: health education; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes
Brief Summary: The purpose of the randomized trial is to quantify the effect of vitamin D and calcium supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for type 2 diabetes.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: Calcium and vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D and calcium suplementation | Intervention Type: DRUG; Name: Vitamin D and calcium suplementation; Assigned to Arm(s): Calcium and vitamin D
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D2 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D2 | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin D2; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D2; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: 1; Type: OTHER; Interventions: Drug: Vitamin D3 2,000 IU orally once daily, Drug: Calcium Carbonate 400 mg orally twice daily | Arm Label: 2; Type: OTHER; Interventions: Drug: Vitamin D3 2,000 IU orally once daily, Drug: Calcium-Placebo | Arm Label: 3; Type: OTHER; Interventions: Drug: Calcium Carbonate 400 mg orally twice daily, Drug: Vitamin D3-Placebo | Arm Label: 4; Type: OTHER; Interventions: Drug: Vitamin D3-Placebo, Drug: Calcium-Placebo | Intervention Type: DRUG; Name: Vitamin D3 2,000 IU orally once daily; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Calcium Carbonate 400 mg orally twice daily; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin D3-Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Calcium-Placebo; Assigned to Arm(s): 2, 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes
Brief Summary: The purpose of the randomized trial is to quantify the effect of vitamin D and calcium supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for type 2 diabetes.


Options:
A: Arm Label: OJ fortified with Ca and VitD; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Orange Juice fortified with Calcium and Vitamin D, Behavioral: Nutritional Counseling | Arm Label: OJ without VitD and Ca; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Orange juice without Ca or VitD, Behavioral: Nutritional Counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Orange Juice fortified with Calcium and Vitamin D; Assigned to Arm(s): OJ fortified with Ca and VitD | Intervention Type: DIETARY_SUPPLEMENT; Name: Orange juice without Ca or VitD; Assigned to Arm(s): OJ without VitD and Ca | Intervention Type: BEHAVIORAL; Name: Nutritional Counseling; Assigned to Arm(s): OJ fortified with Ca and VitD, OJ without VitD and Ca
B: Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: OTHER; Interventions: Drug: Vitamin D3 2,000 IU orally once daily, Drug: Calcium Carbonate 400 mg orally twice daily | Arm Label: 2; Type: OTHER; Interventions: Drug: Vitamin D3 2,000 IU orally once daily, Drug: Calcium-Placebo | Arm Label: 3; Type: OTHER; Interventions: Drug: Calcium Carbonate 400 mg orally twice daily, Drug: Vitamin D3-Placebo | Arm Label: 4; Type: OTHER; Interventions: Drug: Vitamin D3-Placebo, Drug: Calcium-Placebo | Intervention Type: DRUG; Name: Vitamin D3 2,000 IU orally once daily; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Calcium Carbonate 400 mg orally twice daily; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin D3-Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Calcium-Placebo; Assigned to Arm(s): 2, 4
D: Arm Label: vitamin D2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D2 | Arm Label: vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D2; Assigned to Arm(s): vitamin D2 | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): vitamin D3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma
Brief Summary: A Multi-center, Randomized, Placebo, Multi-Dose study to evaluate the efficacy of AMG 317 compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12.


Options:
A: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B
B: Arm Label: 1; Type: OTHER; Interventions: Biological: IMA-638 is a biologic | Intervention Type: BIOLOGICAL; Name: IMA-638 is a biologic; Assigned to Arm(s): 1
C: Arm Label: AMG 317 75 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 75 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: AMG 317 300 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 300 mg | Arm Label: AMG 317 150 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 75 mg; Assigned to Arm(s): AMG 317 75 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 150 mg; Assigned to Arm(s): AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 300 mg; Assigned to Arm(s): AMG 317 300 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma
Brief Summary: A Multi-center, Randomized, Placebo, Multi-Dose study to evaluate the efficacy of AMG 317 compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 0.3 mg/kg, Benralizumab 1.0 mg/kg
C: Arm Label: AMG 317 75 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 75 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: AMG 317 300 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 300 mg | Arm Label: AMG 317 150 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 75 mg; Assigned to Arm(s): AMG 317 75 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 150 mg; Assigned to Arm(s): AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 300 mg; Assigned to Arm(s): AMG 317 300 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comp. | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo Comp.; Assigned to Arm(s): 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma
Brief Summary: A Multi-center, Randomized, Placebo, Multi-Dose study to evaluate the efficacy of AMG 317 compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12.


Options:
A: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
B: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Alair; Type: EXPERIMENTAL; Interventions: Device: Alair System | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Alair System | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Alair | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Sham
D: Arm Label: AMG 317 75 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 75 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: AMG 317 300 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 300 mg | Arm Label: AMG 317 150 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 75 mg; Assigned to Arm(s): AMG 317 75 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 150 mg; Assigned to Arm(s): AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 300 mg; Assigned to Arm(s): AMG 317 300 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: D